Genocea Announces Research Collaboration with Iovance to Explore Development of Neoantigen-Targeted TIL (Tumor-Infiltrating L...
May 16 2019 - 1:00PM
Genocea Biosciences, Inc. (NASDAQ: GNCA), a biopharmaceutical
company developing personalized cancer immunotherapies, today
announced a research collaboration with Iovance Biotherapeutics,
Inc. to assess the potential of applying Genocea’s neoantigen
identification platform, ATLAS™, to next-generation TIL
(tumor-infiltrating lymphocyte) product development.
“We are pleased to collaborate with Iovance, as they are
recognized leaders in TIL therapies,” said Chip Clark, Genocea
President & CEO, “and are excited to explore the utility of
ATLAS, with its ability to identify and characterize neoantigens,
in developing neoantigen-targeted TIL therapies, which would
naturally complement our ongoing personalized cancer vaccine and
cell therapy programs.”
Financial and other terms were not disclosed.
About Genocea Biosciences, Inc.Genocea is a
biopharmaceutical company developing personalized cancer
immunotherapies. Our unique ATLAS technology platform allows us to
identify immunotherapy targets based on each person’s tumor
antigen-specific T cell responses. Using ATLAS, we can both
optimize neoantigens for inclusion in our immunotherapies and
exclude so-called “inhibitory” antigens that appear to exert an
immunosuppressive effect on the patient. We are advancing
complementary programs built from ATLAS insights: GEN-009,
our neoantigen vaccine candidate for which we are conducting a
Phase 1/2a clinical trial across a variety of solid tumor types,
and GEN-011, our neoantigen-specific adoptive T cell therapy, for
which we intend to file an Investigational New Drug Application in
the first half of 2020. To learn more, please visit
www.genocea.com.
Forward-Looking StatementsThis press release
includes forward-looking statements, including statements relating
to new applications of Genocea’s ATLAS technology platform and
Genocea’s intention to file an Investigational New Drug Application
for GEN-011, within the meaning of the Private Securities
Litigation Reform Act. Such forward-looking statements are subject
to risks and uncertainties that could cause actual results to
differ materially from those expressed or implied in such
statements. Genocea cautions that these forward-looking statements
are subject to numerous assumptions, risks and uncertainties that
change over time. Applicable risks and uncertainties include those
identified under the heading "Risk Factors" included in Genocea's
Annual Report on Form 10-K for the year ended December 31, 2018 and
any subsequent SEC filings. These forward-looking statements speak
only as of the date of this press release and Genocea assumes no
duty to update forward-looking statements, except as may be
required by law.
Contact:Jennifer
LaVin617-715-6687jennifer.lavin@genocea.com
Genocea Biosciences (NASDAQ:GNCA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Genocea Biosciences (NASDAQ:GNCA)
Historical Stock Chart
From Sep 2023 to Sep 2024